


Our sponsors:



# ONCOBELL

2018

1<sup>st</sup> International Symposium

**BARCELONA | SEPTEMBER 20-21**

**Auditorium. Bellvitge University Hospital.**

*An international symposium to introduce Oncobell, a new cancer research program within the Bellvitge Biomedical Research Institute (IDIBELL).*



With the collaboration of Astellas Pharma



<http://oncobellsymposium.idibell.cat>

Thursday 20<sup>th</sup>

- 09:00 – 09:45 **Registration**
- 09:45 – 10:00 **Welcome**
- 10:00 – 10:50 **KEYNOTE LECTURE.**  
Chaired by **Ramón Salazar**, IDIBELL  
*Exploiting vulnerabilities of drug-resistant cancer.*  
**René Bernards**, NKI, Amsterdam, Netherlands.
- 10:50 – 11:20 **Coffee Break**
- 11:20 – 13:40 **BRISTOL-MYERS SQUIBB SESSION: CLINICAL RESEARCH.**  
Chaired by **Josep M<sup>a</sup> Piulats**, IDIBELL.  
*The Impact of the Check Point Inhibition Strategies in the Treatment of Hematological Malignancies.*  
**Eva Domingo-Domènech**, IDIBELL, Barcelona, Spain.  
*Harnessing the personalized antitumor T-cell response to treat cancer.*  
**Alena Gros**, VHIO, Barcelona, Spain.  
*Potential and limitations of oncolytic adenoviruses.*  
**Ramón Alemany**, IDIBELL, Barcelona, Spain.  
*Developing a CART19 under "academic conditions". How far can we drive it?.*  
**Manel Juan**, Hospital Clinic, Barcelona, Spain.
- 13:40 – 14:40 **Lunch**
- 14:40 – 17:00 **GENETICS OF CANCER.**  
Chaired by **Laura Valle**, IDIBELL.  
*Genetic susceptibility of colorectal cancer.*  
**Victor Moreno**, IDIBELL, Barcelona, Spain.  
*Clinical impact of genomic studies in chronic lymphocytic leukemia.*  
**Elías Campo**, IDIBAPS, Barcelona, Spain.  
*The challenge of interpreting variants of unknown significance.*  
**Gabriel Capellà**, IDIBELL, Barcelona, Spain.  
*Cross-species analysis of gene regulatory networks in metastatic prostate cancer.*  
**Àlvaro Aytés**, IDIBELL, Barcelona, Spain.

Friday 21<sup>st</sup>

- 09:00 – 11:20 **TARGETING OF SIGNALING PATHWAYS.**  
Chaired by **Cristina Muñoz-Pinedo**, IDIBELL.  
*Insights into mechanisms of prostate cancer resistance.*  
**Mark Rubin**, Bern University, Bern, Switzerland.  
*Immune evasion and metastasis in colorectal cancer.*  
**Eduard Batlle**, IRBB, Barcelona, Spain.  
*The rationale for targeting TGF-beta in hepatocellular carcinoma.*  
**Isabel Fabregat**, IDIBELL, Barcelona, Spain.  
*Targeting the IRBC in c-Myc driven tumors.*  
**George Thomas**, IDIBELL, Barcelona, Spain.
- 11:20 – 12:20 **Poster Session and Coffee Break**
- 12:20 – 13:20 **POSTERS HIGHLIGHTS**  
*The immune response: radio- and immuno-therapy.* **Miguel Angel Berenguer**, IDIBELL.  
*Liquid Biopsy.* **Gabriel Capellà**, IDIBELL.  
*Experimental therapeutics.* **Ernest Nadal**, IDIBELL.  
*Other topics will be considered.*
- 13:20 – 14:10 **KEYNOTE LECTURE.**  
Chaired by **Oriol Casanovas**, IDIBELL  
*Epigenetic signaling pathways controlling invasion and metastasis.*  
**Douglas Hanahan**, ISREC, Lausanne, Switzerland.
- 14:10 – 15:00 **Lunch**
- 15:00 – 16:45 **DRUG RESISTANCE AND MICROENVIRONMENT.**  
Chaired by **Mariona Graupera**, IDIBELL.  
*LIF and the innate immune response. Linking embryology and cancer.*  
**Joan Seoane**, VHIO, Barcelona, Spain.  
*Resistance to Antiangiogenic Therapies by Metabolic Escape via Nucleotide Catabolism.*  
**Oriol Casanovas**, IDIBELL, Barcelona, Spain.  
*Understanding sarcomas: a path to a successful treatment.*  
**Òscar Martínez-Tirado**, IDIBELL, Barcelona, Spain.
- 16:45 – 17:35 **RAMÓN ARECES LECTURE:**  
Chaired by **George Thomas**, IDIBELL  
*Cell Signaling by Receptor Tyrosine Kinases; From Basic Principles to Cancer Therapy.*  
**Joseph Schlessinger**, Yale University, New Haven, USA.
- 17:35 – 17:45 **Closing remarks**